Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Long term efficacy and safety in children and young adults with treatment resistant epilepsy treated with Cannabidiol

Trial Profile

Long term efficacy and safety in children and young adults with treatment resistant epilepsy treated with Cannabidiol

Status: Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 12 Jul 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Epilepsy
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Most Recent Events

    • 12 Jul 2018 Interim results (n=607) on the safety and efficacy of cannabidiol in expanded-access program patients treated through December 2016, published in the Epilepsia Journal.
    • 03 Jan 2018 New trial record
    • 05 Dec 2017 Results presented at the 71st Annual Meeting of the American Epilepsy Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top